Abstract:Racial and ethnic inequities in the receipt of medications to treat opioid use disorder (MOUD) have been well described. Ross and colleagues 1 provide an important addition to the existing literature on MOUD disparities, identifying racial differences in buprenorphine and methadone dosing across 3 trials completed within the National Institute on Drug Abuse Clinical Trials Network (CTN). Similar to prior research, Ross and colleagues 1 found a significant difference among methadone dosing among Non-Hispanic Black compared with Non-Hispanic White participants in their fully adjusted models. 2 Additionally, Ross and colleagues 1 describes differences in mean buprenorphine dosing and the proportion of participants receiving high buprenorphine or methadone doses among Non-Hispanic Black compared with Non-Hispanic White participants. Dosing disparities are particularly concerning because higher MOUD doses have been associated with greater retention in treatment. 3 While the differences identified were not significant after covariate adjustment (sex, age, withdrawal symptom severity, comorbid conditions, and drug use history), overadjustment and small sample sizes, particularly for the Non-Hispanic Black and Hispanic participants, may have limited the findings. The findings of Ross et al 1 must be understood in the context of the national randomized clinical trials whose data they analyzed. The first trial, the START trial (2006-2010), compared buprenorphine-naloxone and methadone in patients with opioid use disorder (OUD) with a primary outcome of liver function at 6 months (CTN-0027). Of note, a larger percentage of White participants who gave consent were screened out prior to randomization (75% vs 64%). 4 The second trial (2006-2009), the POATS study (CTN-0030 Phase 2), evaluated various doses of buprenorphine-naloxone with and without counseling for individuals with prescription opioid dependence, with a primary outcome of abstinence from nonprescribed opioids. Of note, this trial had the lowest rate of Non-Hispanic Black and Hispanic participants (7.5% compared with 27% in CTN-0027 and 30% in CTN-0051). Finally, the third trial, the X:BOT study (2014-2016), compared the effectiveness of intramuscular naltrexone vs buprenorphine-naloxone (CTN-0051). The first 2 trials took place prior to the introduction of fentanyl in the drug supply, with its emergence overlapping with CTN-0051. The Ross et al 1 secondary analysis pooled heterogeneous data on buprenorphine and methadone dosing and evaluated differences by race and ethnicity during the first 4 weeks of treatment. All studies included randomized treatment assignment and participants were from sites across the country. Each trial protocol provided similar dosing recommendations and allowed clinicians the flexibility to make adjustments based on clinical or subjective opioid withdrawal scores and clinical judgment. For a patient initiating methadone or burprenorphine to stabilize, a number of steps are necessary. First, they need to be assessed for, and diagnosed with, OUD. Then, they need access to a clinician who can prescribe MOUD or admission to an opioid treatment program, both of which require overcoming stigma, insurance, and transportation-related barriers. If the patient receives buprenorphine, certain insurance plans require prior authorizations for higher doses, mandate behavioral treatment attendance, or require frequent urine drug testing. 5 These barriers can be factors in stigma against addiction and may require additional clinical resources, which limits timely access to medications. For individuals receiving methadone, they typically must attend a specialized clinic daily and receive their medications under supervision. These clinics are only available in certain geographic areas and are often concentrated in high-poverty neighborhoods. Once a medication has been initiated, identifying stabilization with the right dose often requires frequent dose adjustments over several weeks. Finally, individuals must continue to take the medication as prescribed, attend follow-up visits, and meet treatment program requirements. Each step is subject to individual biases from clinicians, stigma against addiction, and structural racism in and outside of the health care setting–hindering progression along the OUD cascade of care. Policies within health care organizations, as well as state and national restrictive opioid-related policies, have had a negative impact in patient access to care and retention in care, especially for Black patients. While the clinical trial setting removes many barriers to medication access early in this pathway once enrolled, disparities in trial enrollment by race can affect the generalizability of the findings and limit confidence in the effectiveness of new treatments in clinical settings whe -Abstract Truncated-

Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study

Association Between Length of Buprenorphine or Methadone Use and Nonprescribed Opioid Use Among Individuals with Opioid Use Disorder: A Cohort Study

Assessing predictors of adequate individual buprenorphine maintenance dosage for the treatment of opioid use disorder: Listening to the patient

Characterising methamphetamine/amphetamine use among opioid agonist therapy‐seeking adults with prescription‐type opioid use disorder in Canada

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder

Sexually transmitted and blood‐borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder: Findings from a Canadian pragmatic randomized trial

Methadone Dosing at New York State Opioid Treatment Programs Following Initial Revisions to Federal Regulations

Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization

Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA

Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder

Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data

Randomised clinical trial of a 16 mg vs 24 mg maintenance daily dose of buprenorphine to increase retention in treatment among people with an opioid use disorder in Rhode Island: study protocol paper

Client and program-level factors associated with planned use of medications for opioid use disorder in specialty substance use treatment programs: Evidence from linked administrative data and survey data

Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type

Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation

Dosing Inequities in Opioid Use Disorder Treatment Trials

Reconsidering the usefulness of long-term high-dose buprenorphine

Benzodiazepine Use in Opioid Maintenance Treatment Programme: Risks and Clinical Outcomes

Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale

Trends in polysubstance use among patients in methadone maintenance treatment in Ireland: Evidence from urine drug testing 2010-2020

Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life